Amphastar v. Aegis Therapeutics: Federal Circuit Dismisses Epinephrine Patent Appeal
Amphastar Pharmaceuticals challenged Aegis Therapeutics’ US10682414B2, a patent covering intranasal epinephrine formulations and disease treatment methods, before the Court of Appeals for the Federal Circuit. The appeal was dismissed without a merits ruling after 683 days, leaving the underlying patent position unresolved by the appellate court.
Federal Circuit closes epinephrine patent appeal on procedural grounds
Amphastar Pharmaceuticals, Inc. filed this infringement-related appeal at the Court of Appeals for the Federal Circuit on 24 April 2023, targeting Aegis Therapeutics, LLC’s US10682414B2 — a patent directed to intranasal epinephrine formulations and associated methods for treating disease. The appeal, designated Case No. 23-1783, arose from a District of Columbia-region dispute and was litigated by Perkins Coie LLP for Amphastar and Mintz Levin for Aegis Therapeutics.
The Federal Circuit dismissed the proceeding on 7 March 2025 under the basis of termination recorded as ‘Appeal Dismissed.’ The court issued no merits ruling on the validity or infringement questions related to US10682414B2. A dismissal at the appellate level without merits adjudication typically means the appeal was terminated for procedural, jurisdictional, or standing-related reasons rather than on the substance of the patent dispute.
The 683-day duration before dismissal suggests the matter progressed through at least some substantive procedural stages before resolution, which is consistent with motion practice or jurisdictional briefing before dismissal. The public record does not disclose whether the dismissal was voluntary or court-initiated, nor whether the underlying district-level proceedings remain active or were separately resolved. The enforceability of US10682414B2 remains undetermined by this appellate proceeding.
Filing to Appeal Dismissed in 683 days
683 days from filing to dismissal — longer than the median Federal Circuit appeal
Appeal dismissed: what the Federal Circuit’s termination means for both parties
Dismissed without a merits ruling — patent validity left open
The Federal Circuit dismissed this appeal as a procedural matter, issuing no ruling on the validity or infringement of US10682414B2. An appellate dismissal of this kind typically reflects a jurisdictional defect, lack of standing, mootness, or a procedural bar — not a substantive finding on the patent’s merits. The underlying legal questions concerning the intranasal epinephrine formulation patent remain unresolved at this court level.
No merits adjudicationAmphastar’s challenge fails to secure a Federal Circuit ruling
As appellant, Amphastar Pharmaceuticals did not obtain the appellate review it sought. The dismissal means no Federal Circuit judgment was issued in its favour on the patent challenge. Amphastar’s strategic options going forward depend on whether the dismissal forecloses re-filing or whether the underlying district-level proceedings remain a live vehicle for challenging US10682414B2. The public record is silent on the precise grounds for dismissal.
Appeal unsuccessfulAegis Therapeutics retains patent without appellate invalidation
Aegis Therapeutics, as appellee and patent holder, benefits from the dismissal in that US10682414B2 was not invalidated or narrowed by the Federal Circuit. However, the absence of a merits ruling also means the patent received no affirmative appellate validation. Aegis cannot point to this proceeding as judicial confirmation of the patent’s strength, and future challenges remain possible through other proceedings.
Patent survives this challengeIntranasal epinephrine IP landscape remains contested
The dismissal without merits resolution leaves market participants in the intranasal epinephrine space without appellate guidance on the scope or validity of US10682414B2. Competitors, generic manufacturers, or alternative drug delivery developers in this space should treat this outcome as inconclusive — the patent’s enforceability is neither confirmed nor denied by this Federal Circuit proceeding. Freedom-to-operate analysis remains essential.
IP landscape unresolvedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Amphastar Pharmaceuticals, Inc. | Company | Specialty pharmaceutical company — appellant and challenger of US10682414B2Search in Eureka ↗ |
| Defendant | AEGIS THERAPEUTICS, LLC | Company | Aegis Therapeutics, LLC — drug delivery technology company and holder of US10682414B2Search in Eureka ↗ |
| Plaintiff counsel | Andrew Dufresne | Attorney | Counsel for Amphastar Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Emily Jane Greb | Attorney | Counsel for Amphastar Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Matthew A. Lembo | Attorney | Counsel for Amphastar Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Nathan K. Kelley | Attorney | Counsel for Amphastar Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Nathanael D. Andrews | Attorney | Counsel for Amphastar Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Perkins Coie LLP | Law Firm | Representing Amphastar Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Adam Phillip Samansky | Attorney | Counsel for AEGIS THERAPEUTICS, LLCSearch in Eureka ↗ |
| Defendant counsel | Nana Liu | Attorney | Counsel for AEGIS THERAPEUTICS, LLCSearch in Eureka ↗ |
| Defendant counsel | Thomas H. Wintner | Attorney | Counsel for AEGIS THERAPEUTICS, LLCSearch in Eureka ↗ |
| Defendant law firm | Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC | Law Firm | Representing AEGIS THERAPEUTICS, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order that ‘the proceeding is DISMISSED’ under the basis of ‘Appeal Dismissed’ is a procedural termination rather than a substantive ruling. No standard of review was applied to the merits of the underlying infringement or validity questions concerning US10682414B2. The phrasing is consistent with a dismissal for lack of jurisdiction, standing deficiency, or mootness — all of which terminate appellate review without binding precedent on the patent’s scope or validity. Neither party obtained a merits judgment from this court.
US10682414B2 — Intranasal epinephrine formulations and disease treatment methods
US10682414B2, filed under application number US16/420044, protects intranasal epinephrine formulations and the methods by which they are used to treat disease. Epinephrine delivered intranasally represents an important alternative to injectable formats — particularly relevant for anaphylaxis and emergency use cases where needle administration is impractical. The patent’s claims likely encompass specific formulation parameters, delivery mechanisms, and excipient compositions that define Aegis Therapeutics’ proprietary approach to nasal epinephrine delivery.
Strategically, US10682414B2 sits at the intersection of emergency medicine and drug delivery innovation — a commercially high-value space given the broad installed base of epinephrine auto-injectors and growing clinical interest in needle-free alternatives. Any pharmaceutical company developing intranasal epinephrine products, including generic or reformulated versions, must assess this patent’s claim scope carefully. The involvement of Amphastar — a major injectable and inhalation drug manufacturer — as appellant suggests the patent was perceived as a meaningful barrier to market entry or competitive product development.
Should your product team run an FTO against US10682414B2?
Any R&D team developing intranasal epinephrine formulations, needle-free emergency drug delivery systems, or related nasal drug delivery platforms should treat US10682414B2 as a priority FTO target. The patent survived this Federal Circuit appeal without invalidation, and Aegis Therapeutics has demonstrated willingness to defend its position in litigation. Companies filing ANDAs, developing 505(b)(2) products, or building proprietary nasal delivery technologies in the epinephrine space face direct exposure without a current clearance opinion.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US10682414B2, identify the full Aegis Therapeutics patent family including any continuations or divisionals, and surface prior art that may support a future invalidity challenge. Eureka can also flag related prosecution history and any inter partes review filings that may affect enforceability — giving your legal and product teams a complete, up-to-date clearance picture before committing to development investment.
Run a freedom-to-operate analysis on US10682414B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in intranasal and specialty drug delivery patent disputes
Explore Federal Circuit appeals involving intranasal drug delivery patents and pharmaceutical formulation infringement disputes comparable to Amphastar v. Aegis Therapeutics.
What this case signals for the intranasal drug delivery IP landscape
A Federal Circuit dismissal without merits leaves the intranasal epinephrine patent field in an uncertain state that demands proactive IP monitoring.
Procedural dismissals do not resolve validity — monitor the patent actively
US10682414B2 has now survived a Federal Circuit appeal without judicial scrutiny of its merits. For any company active in intranasal epinephrine or related drug delivery formulations, this means the patent remains a live enforcement risk. Ongoing monitoring of Aegis Therapeutics’ patent portfolio and any continuation applications is advisable.
Amphastar’s challenge path may shift to alternative venues
Following an appellate dismissal, challengers typically reassess their strategy — options may include inter partes review at the USPTO, re-engagement at the district court level, or a redesigned product approach. Companies watching this dispute should track whether Amphastar pursues any further challenge proceedings against US10682414B2.
Amphastar v AEGIS — key questions answered
The Federal Circuit dismissed Amphastar’s appeal in Case 23-1783 on 7 March 2025 without issuing any merits ruling. The appeal concerned US10682414B2, Aegis Therapeutics’ patent covering intranasal epinephrine formulations and disease treatment methods. The dismissal was procedural in nature, leaving the patent’s validity and enforceability unresolved by the appellate court.
US10682414B2, held by Aegis Therapeutics and filed under application US16/420044, covers intranasal epinephrine formulations and methods for treating disease. It is commercially significant because it protects a needle-free alternative to injectable epinephrine — a format with strong demand in emergency allergy and anaphylaxis treatment. The patent’s scope is directly relevant to any company developing competing intranasal epinephrine products or ANDA filings in this category.
The public record identifies the basis of termination as ‘Appeal Dismissed’ but does not specify the precise grounds. Federal Circuit appeals are typically dismissed for procedural reasons including lack of appellate jurisdiction, mootness, lack of standing, or voluntary withdrawal. No merits ruling was issued, suggesting the court did not reach the substantive patent questions raised by Amphastar.
The dismissal without prejudice to the merits suggests Amphastar may retain the ability to challenge US10682414B2 through other mechanisms, including inter partes review (IPR) at the USPTO or renewed district court proceedings, depending on the specific grounds for dismissal. Patent attorneys advising Amphastar would need to assess estoppel, timing, and standing implications before pursuing any further challenge route.
US10682414B2 represents a live enforcement risk for any company developing intranasal epinephrine products, including generic manufacturers, 505(b)(2) applicants, and novel delivery platform developers. The Federal Circuit’s procedural dismissal in Case 23-1783 provides no invalidity clearance. A thorough FTO analysis covering the full Aegis Therapeutics patent family, claim scope, and prosecution history is recommended before any product launch or ANDA submission in this space.
PatSnap Eureka searches patents and litigation data to answer instantly.